Endemic vs. Non-Endemic Media for Pharma
Endemic vs non-endemic media for pharma: medical publishers, EHR, and point of care compared with open web, CTV, and social on cost, reach, and context.
The short answer
Endemic media is health-specific: medical publishers, professional networks, EHR platforms, and point-of-care screens. Non-endemic media is the open web, CTV, streaming audio, and social. Endemic costs more per impression but delivers concentrated HCP audiences in a clinical context. Non-endemic delivers reach and lower CPMs, with more waste and weaker context. HCP plans usually weight endemic more heavily, while DTC plans lean non-endemic.
The endemic versus non-endemic question often decides more budget than any targeting choice. A specialty brand can put most of its HCP budget into two or three endemic partners, or it can run NPI-targeted programmatic across the open web and keep endemic as a smaller premium layer. Both can work. The mistake is deciding on CPM alone.
What counts as endemic and non-endemic
Endemic channels exist because of healthcare. Medical news and journal sites, physician communities and professional networks, drug reference apps, EHR and e-prescribing platforms, and point-of-care networks (waiting room screens, exam room tablets, pharmacy screens). Consumer health publishers are often counted as endemic for DTC purposes.
Non-endemic channels are general: news, sports, and lifestyle sites on the open web, CTV and streaming video, streaming audio and podcasts, social platforms, and search. HCPs use these too, which is why NPI-targeted programmatic on non-endemic inventory exists. For the HCP buying paths across both, see HCP programmatic advertising channels.
Endemic vs. non-endemic: the tradeoffs
| Factor | Endemic | Non-endemic |
|---|---|---|
| Cost per impression | Higher, often sold direct or through PMPs | Lower, especially open auction |
| Audience concentration | High; most visitors to a professional site are clinicians | Low unless targeted by NPI or audience data |
| Reach | Capped by each platform's user base | Large, but limited by match rates for HCP targeting |
| Context | Clinical; the reader is often thinking about patients | Mixed; the HCP may be off duty |
| Formats | Display, native, sponsored content, alerts, workflow messages | Display, video, CTV, audio, social |
| Measurement | Many platforms report at NPI level and support Rx lift studies | Depends on exposure file quality and identity match |
| Supply quality risk | Lower, but verify claims about audience composition | Higher; MFA sites and resold paths are common |
Two points get missed. First, endemic audience claims need checking too. Ask how a platform verifies that users are clinicians and what share of impressions reach your target list, not just "HCPs." Second, non-endemic CPMs are low partly because some of the supply is low quality. The ANA's programmatic supply chain transparency study found a meaningful share of open-web spend going to made-for-advertising and other low-value inventory, and healthcare is not exempt.
Cost: compare on the unit that matters
CPM comparisons favor non-endemic almost every time, and that comparison is misleading. Compare on cost per target HCP reached or, better, cost per incremental outcome.
An illustrative example. An endemic placement costs $60 CPM and 70 percent of impressions reach NPIs on the target list. Non-endemic NPI-targeted display costs $15 CPM and 35 percent of impressions reach target NPIs once match error and list drift are accounted for. Cost per thousand on-target impressions is about $86 for endemic ($60 divided by 0.70) and about $43 for non-endemic ($15 divided by 0.35). Non-endemic still wins on that measure, but by 2 times, not 4 times. If the endemic context produces higher engagement per impression, which the measurement should test, the gap can close further or reverse.
Context and measurement
Context is the hardest factor to price. An ad seen inside an EHR while the physician is choosing a therapy is a very different exposure from a banner on a sports score page. The FDA rules on the ad itself are the same in both places, but attention and relevance are not. Point-of-care and EHR messaging also raise their own review questions, because the ad sits close to clinical decision making.
On measurement, endemic partners often have cleaner exposure data because they know who their users are. Non-endemic exposure files depend on the identity match, so errors in the match carry into the Rx lift study. If you are running a lift study, check both data paths before launch. For consumer campaigns, the closest equivalent to endemic is contextual targeting on health content, covered in pharma contextual advertising.
An illustrative allocation
These splits are illustrative starting points for planning, not benchmarks. They should be adjusted by audience size, measured results, and partner reach overlap.
| Brand situation | Endemic share (illustrative) | Non-endemic share (illustrative) | Reasoning |
|---|---|---|---|
| Specialty HCP, under 5,000 targets | 60 to 70 percent | 30 to 40 percent | Small list, endemic concentration matters, open web adds frequency |
| Primary care HCP, 50,000+ targets | 40 to 50 percent | 50 to 60 percent | Endemic cannot reach the full list at needed frequency |
| DTC, common condition | 15 to 25 percent | 75 to 85 percent | Reach comes from CTV, video, and social; endemic for high-intent moments |
| DTC, rare condition | 30 to 40 percent | 60 to 70 percent | Health content concentrates a scarce audience; non-endemic for caregivers and broader awareness |
Before committing, run an overlap check between endemic partners and your NPI list. Two endemic partners reaching the same 40 percent of a list do not double the reach. The budget logic for splitting by tactic and test is in how to allocate a pharma programmatic budget.
Practical takeaway
Ask every endemic and non-endemic partner for the same number: the share of last quarter's delivered impressions that reached NPIs on your target list, verified against your own list. Divide CPM by that share to get cost per thousand on-target impressions, then use that, not CPM, to set the starting split. The healthcare programmatic guide covers where this decision sits in the wider plan.
Frequently asked questions
What is endemic media in pharma?
Endemic media is advertising on platforms whose content and audience are medical or health focused: medical news and journal sites, professional networks, EHR and e-prescribing platforms, and point-of-care networks in clinics and pharmacies. Non-endemic media is everything else, such as the open web, CTV, and social platforms.
Is endemic media worth the higher CPM?
Often, for HCP campaigns, because a larger share of impressions reaches the intended audience in a relevant context. The right comparison is cost per verified target HCP reached, or cost per incremental outcome, not CPM. For DTC campaigns, non-endemic channels usually carry most of the reach.
How should a pharma brand split budget between endemic and non-endemic?
It depends on audience size, the outcome being measured, and how much each channel adds in unique reach. Many HCP plans weight endemic more heavily and use non-endemic NPI targeting for frequency and reach extension, while DTC plans do the opposite. Test the split rather than copying a benchmark.
Sources
- FDA, Basics of Drug Ads
- Media Rating Council, Standards and Guidelines
- ANA, Programmatic Media Supply Chain Transparency Study
- IAB Tech Lab, sellers.json
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.